RNAi Roundup: Scaringe, Back Out Front, Discusses Dharmacon s Abbott Deal and Its Strategy; Alnylam Licenses Polymer Drug Delivery IP and Hires Vincent Miles; And Others | GenomeWeb

NEW YORK, Aug. 1 - Dharmacon's new deal to provide Abbott with a library of short-interfering RNAs for drug target genes is not just another gold star for the company, according to Stephen Scaringe, who has recently taken a new title of Chief Scientific officer and co-chairman.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.